Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Goldman

Showing results (301-310 of 305) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 305 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialK Jhaveri, L D Eli, H Wildiers, et al.
Journal of Biological Rhythms|August 3, 2012
Learning chronobiology by improving WikipediaC D Chiang, C L Lewis, M D E Wright, et al.
Cancer Research|August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 ImmunotherapyLeanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Nature|February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 31

Showing results (301-310 of 305) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 305 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trialK Jhaveri, L D Eli, H Wildiers, et al.
Journal of Biological Rhythms|August 3, 2012
Learning chronobiology by improving WikipediaC D Chiang, C L Lewis, M D E Wright, et al.
Cancer Research|August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 ImmunotherapyLeanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Nature|February 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 31